

# RATHER

Rational Therapy for Breast Cancer

**6 Academic Partners**



**2 Collaborating SMEs**



**4 Clinical Trials underway**

**> 120 patients recruited**



**Further Funding Leveraged  
€17.9 million**



**Initial EU Funding  
€6 million**

**4 Patents Filed**

**1 Prognostic assay validated for ILC**




Protein kinases  
**Improved survival**  
 Clinical trials Patients  
**Better outcomes**  
 Novel  
**Collaboration**  
 Biomarkers New  
**Triple Negative Breast Cancer**  
 Therapeutic targets  
 Companion diagnostics  
 Invasive Lobular Carcinoma


**19 Original Articles**

**3 Review Articles**

**85 Presentations**




**New Discoveries**



**New biomarkers for TN\* and ILC\*\***  
**New biomarker signatures for TN and ILC**  
**New treatment strategies for TN and ILC**

**>70 in RATHER team working over 7.5 years**



\*TN - Triple Negative Breast Cancer

\*\* ILC - Invasive Lobular Carcinoma